title: Can a Joint Assessment Provide Relevant Information for National/Local Relative Effectiveness Assessments? An In-Depth Comparison of Pazopanib Assessments.
abstract: BACKGROUND
  In many European jurisdictions, relative effectiveness assessments (REAs) of pharmaceuticals are performed during the reimbursement decision-making process. International collaboration in the production of these assessments may prevent the duplication of information in various jurisdictions. A first pilot of a joint REA (pazopanib for the treatment of renal cell carcinoma) was published in 2011.
  
  
  OBJECTIVE
  The objective was to investigate how well the methods used in the joint REA match the methods used in the national/local assessments on the same topic.
  
  
  METHODS
  National/local assessments from European jurisdictions, available in English language, were identified through a literature search and an e-mail request to health technology assessment organizations. Data were abstracted from joint and national/local assessments using a structured data abstraction form. Results were compared for differences and similarities.
  
  
  RESULTS
  In total, five national/local reports were included (Belgium, England/Wales, France, The Netherlands, and Scotland). The general methods (indication, main comparator, main end points, main trial) were similar. The details of the assessment (e.g., exact wording of indication, additional comparators, additional trials included, and method of indirect comparison), however, varied. Despite these differences, the joint REA included nearly all comparators, end points, trials, and methods of analysis that were used in national/local REA reports.
  
  
  CONCLUSIONS
  This study has shown overlap in the methods national/local REA bodies in Europe have chosen for a pazopanib REA for renal cell carcinoma, except for the use and methods of indirect comparisons. Although some additional comparators and outcomes differed between national/local REAs, they can be captured in a comprehensive joint REA.
authors: National Health Care Institute, Diemen, Netherlands; Faculty of Science, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, Netherlands. Electronic address: skleijnen@zinl.nl.
authors: Sarah
authors: S
authors: Kleijnen
authors: University of Utrecht, Utrecht, Netherlands.
authors: Mohammed
authors: M
authors: Fathallah
authors: National Health Care Institute, Diemen, Netherlands.
authors: Michiel W
authors: MW
authors: van der Linden
authors: National Institute for Health and Disability Insurance, Brussels, Belgium.
authors: Piet
authors: P
authors: Vancraeynest
authors: National Authority for Health, Paris, France.
authors: Bachir
authors: B
authors: Dahmani
authors: Scottish Medicines Consortium and Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom.
authors: Angela
authors: A
authors: Timoney
authors: Faculty of Science, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, Netherlands.
authors: Anthonius
authors: A
authors: De Boer
authors: Faculty of Science, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, Netherlands.
authors: Hubertus G
authors: HG
authors: Leufkens
authors: National Health Care Institute, Diemen, Netherlands; Faculty of Science, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, Netherlands.
authors: Wim G
authors: WG
authors: Goettsch
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics*; D057186:Comparative Effectiveness Research; D003299:Cooperative Behavior; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D016527:Drug Costs; D005060:Europe; D006801:Humans; D007191:Indazoles; D007349:Insurance, Health, Reimbursement; D007391:International Cooperation; D007680:Kidney Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics*; D018803:Models, Economic; D000091402:Prohibitins; D011743:Pyrimidines / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D013449:Sulfonamides / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D007191:Indazoles; C000717331:PHB2 protein, human; D000091402:Prohibitins; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib
keywords: comparative effectiveness; health technology assessment; pharmaceuticals; reimbursement